Skip to content

Released Aug 7, 2023, before the open

10-Q filed Aug 7, 2023, 38 days after period end · 0001558370-23-013483

Q2 2023 · 10-Q
Revenue$35.08M+300.7% vs Q2 2022+265.8% vs Q1 2023
Net Income$19.34MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted$0.21N/M vs Q2 2022N/M vs Q1 2023
Operating Income$20,421,000N/M
Operating Cash Flowderived$4,973,000N/M
Free Cash Flowderived$4,769,000N/M
Margins · derived
Operating margin58.2%+121.3 pt vs Q2 2022
Net margin55.1%+116.1 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$35.08M$8.75M$6.43M$10.97M
Net Income$19.34M-$5.33M-$11.24M-$4.15M
EPS Diluted$0.21-$0.11-$0.25-$0.13

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR